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tion studies related to generic HRQOL instruments. To achieve
parity with developments elsewhere regionally-relevant research
in this ﬁeld is a priority.
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CLINICAL PREVENTION PROGRAM ON MEDICATION USE
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The Healthy Families Succeed Pilot used nurse-pharmacists
teams to test the effects of a home visitation, family-centered,
clinical prevention intervention on health, service utilization and
self-sufﬁciency. OBJECTIVES: 1) Describe the types of medica-
tion-related interventions of the teams; 2) determine factors asso-
ciated with polypharmacy; and 3) determine the impact the
teams had on adherence. METHODS: Design: randomized, two
group comparison. Selection: Inclusion criteria: use of multiple
state programs and polypharmacy (≥10 unique drugs/year).
Exclusion: age ≥ 65, incarceration. Process: Two nurse-pharma-
cist teams participated. Nurses made home visits throughout the
pilot study. Pharmacists reviewed records, made home visits and
served as consultants to the nurses and families. Analysis: Inter-
views with the teams were used to collect data related to the
interventions and families’ patterns of medication use. Regres-
sion analysis was performed on integrated health and social
claims data to identify factors related to polypharmacy and
adherence to medication regimens (measured by medication pos-
session ratios). RESULTS: Thirty-ﬁve families were assigned to
the study group and 33 in the control group. The teams found
medication problems in 97% of the intervention households.
Problems included: adherence (44%); lack of disease control
(37%); administration/storage problems (30%); ADR/interac-
tions (25%); and no indication for medication use (28%).
Factors associated with poly-pharmacy included: increasing age,
female gender, number of providers, number of ER visits, pres-
ence of a mental health or respiratory diagnosis, number of 
diagnoses, and county of residence. Medication ﬁlls/month and
average MPR increased, while the number of unique drugs
declined in the study group, relative to the control group. CON-
CLUSIONS: Most medication problems were related to lack of
understanding. Poor adherence was commonly associated with
lack of timely access to understandable information. Families
used the education and support provided by the teams to
improve adherence. Polypharmacy is an effective measure for
identifying families in need of clinical prevention.
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AND PHARMACEUTICAL SERVICES WITHIN AMBULATORY
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OBJECTIVES: The objectives of this study were to: 1) examine
the exposure rates to clinically important drug-drug interactions
(DDIs) within ambulatory care setting of the Veterans Affairs
Medical Centers (VAMCs), and 2) examine the association
between the structure of pharmaceutical services within the
ambulatory care setting of the VAMCs and DDI exposure rates.
METHODS: The study employed an observational, descriptive,
cross-sectional design, consisting of a retrospective database
analysis of pharmacy records to identify the exposure rate of
potential DDIs, and a mailed questionnaire to pharmacy direc-
tors to collect information about the characteristics of pharma-
ceutical services within the ambulatory care setting of VAMCs.
The time frame employed to identify DDI exposures was
between July 1, 2003 and June 30, 2004. A multivariate regres-
sion model was used to assess the association between domains
of pharmaceutical services and exposure rates to potential DDIs.
RESULTS: Pharmacy records from 2,795,345 veterans who ﬁlled
prescriptions at 128 VAMCs were analyzed. Overall, the rate 
of exposure to potential DDIs was 21.54 per 1,000 veterans
exposed, ranging from 9.65 to 32.32. Of the 563 ambulatory
clinics, 272 (48.3%) had pharmacist coverage. Anticoagulation
clinics were the most commonly reported ambulatory clinics, and
clinical pharmacy services were most commonly reported in ther-
apeutic drug monitoring clinics. After controlling for the total
number of pharmacists on staff, lower rates of potential DDIs
were observed in VAMCs with a higher number of specialty
ambulatory clinics and lower prescription volumes (p < 0.05).
CONCLUSION: The study observed wide variation in the rate
of exposure to clinically important DDIs within VAMC ambu-
latory care settings. Lower rates of exposure to potential DDIs
were noted in VAMCs with a higher number of specialty ambu-
latory clinics and lower prescription volumes.
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OBJECTIVES: The effectiveness of Medication Therapy Man-
agement Programs (MTMP), as deﬁned in the Medicare Mod-
ernization Act, at reducing adverse drug events (ADEs) may vary
depending on the MTMP structure and delivery method. The
cost-effectiveness of such programs are not known. To estimate
the break-even and cost-effectiveness thresholds for MTMP spe-
cialized in ADE prevention in ambulatory patients from a third
party payer perspective. METHODS: A Markov model was
developed using a hypothetical cohort of 1,000 patients. A sys-
tematic review was conducted to estimate probabilities and costs
for preventable and non-preventable ADEs, and the associated
permanent disability and mortality. Breakeven and cost-
effectiveness analyses were conducted by altering the effective-
ness of the MTM program at reducing preventable ADEs and
calculating 10-year costs, life expectancy, and breakeven points.
RESULTS: Probabilities and costs were primarily obtained from
a cohort study of all Medicare enrollees (30397 person-years of
observation) cared by a multispeciality group practice during a
12-month study period. As the relative risk reduction of the
MTM program on preventable ADEs was varied from 0.1 to 1,
the 10-year cost offset (breakeven cost) of the MTM program
varied from $75,500 to $272,900 per 1000 persons, life years
gained varied from 0.9 to 8.2 per 1000 persons, healthy life years
gained varied from 1.3 to 11.6 per 1000 persons. Assuming a
cost-effectiveness threshold of $100,000, the 10-year costs of the
MTM program could approach $160,500 (RRR = 0.1) to
$1,432,900 (RRR = 1) per 1000 persons to be considered cost-
effective. CONCLUSION: The breakeven points for MTM 
programs specialized in ADE prevention were realistic and
attainable. Generally speaking, MTM programs should be
viewed as cost-effective. The cost-effectiveness of individual pro-
grams will depend heavily on the effectiveness of such programs
in reducing preventable ADE’s, as demonstrated by the wide
range in breakeven points.
